Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 29, 2022 09:00 ET | Source: Medical Marijuana, Inc.

Medical Marijuana, Inc. Issues New Letter to Shareholders

SAN DIEGO, CA, March 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire - Medical Marijuana, Inc. (OTC: MJNA) (the "Company"), the first-ever publicly traded cannabis company in the United States that...
March 15, 2022 07:00 ET | Source: Passage Bio

Passage Bio Provides Update on Strategic Priorities and Extends Cash Runway

Company to reduce workforce and prioritize research and development programs to reduce operating expensesContinued focus on execution of three ongoing clinical trials for GM1 gangliosidosis, Krabbe...
March 10, 2022 07:00 ET | Source: Passage Bio

Passage Bio Doses First Patient in Global Clinical Trial for Infantile Krabbe Disease, A Rare Fatal Pediatric Condition

PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
February 16, 2022 05:00 ET | Source: Gold River Productions, Inc.

Gold River Productions, Inc. (GRPS) appoints Aerospace Engineer Dr. Gabe Vlad, Chief Technical Officer

Palm Coast, FL, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Gold River Productions, Inc. (OTC Pink: GRPS) announces the appointment of Defense Aerospace engineer and executive Dr. Gabe Vlad as Chief Technical...
February 11, 2022 11:00 ET | Source: Passage Bio

Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposium

Both children with late infantile GM1 gangliosidosis in Cohort 1 of the Imagine-1 clinical trial showed developmental improvement in assessments by study investigators and caregiversInterim safety...
February 11, 2022 07:00 ET | Source: Sio Gene Therapies

Sio Gene Therapies Announces Corporate Updates and Fiscal Third Quarter 2021 Financial Results

Company prioritizing industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff disease$81.9...
February 09, 2022 08:00 ET | Source: TigerGraph, Inc.

TigerGraph Launches Million-Dollar Challenge to Inspire Innovative Uses of Graph

REDWOOD CITY, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- TigerGraph, provider of a leading graph analytics platform, today launched “Graph for All Million Dollar Challenge”, a global search for...
February 09, 2022 08:00 ET | Source: TigerGraph, Inc.

TigerGraph Launches Million-Dollar Challenge to Inspire Innovative Uses of Graph

REDWOOD CITY, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- TigerGraph, provider of a leading graph analytics platform, today launched “Graph for All Million Dollar Challenge”, a global search for...
February 09, 2022 08:00 ET | Source: TigerGraph, Inc.

TigerGraph Launches Million-Dollar Challenge to Inspire Innovative Uses of Graph

DELHI, India, Feb. 09, 2022 (GLOBE NEWSWIRE) -- TigerGraph, provider of a leading graph analytics platform, today launched “Graph for All Million Dollar Challenge”, a global search for innovative...
February 09, 2022 08:00 ET | Source: TigerGraph, Inc.

TigerGraph Launches Million-Dollar Challenge to Inspire Innovative Uses of Graph

REDWOOD CITY, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- TigerGraph, provider of a leading graph analytics platform, today launched “Graph for All Million Dollar Challenge,” a global search for...